TORNTPHARM
Torrent Pharmaceuticals Limited
Each stock's 10,000-path forecast, rendered as light.
Torrent Pharmaceuticals Limited (TORNTPHARM) Stock Analysis & Case Study
Is TORNTPHARM a good buy? The data-driven verdict.
Torrent Pharmaceuticals Limited (TORNTPHARM) trades at ₹4,924,on the numbers it worth a closer look, a Downstox Snapshot Score of 59/100.
On the numbers, Torrent Pharmaceuticals Limited (TORNTPHARM) worth a closer look, a Downstox Snapshot Score of 59/100, weighing expensive at 83.9× earnings, ROE of 27.4%, a 70% model probability of trading higher in a year. Below: the full bull case, bear case, sector-relative valuation, and a probability-weighted price target for 2027-2031.
Last updated . Data snapshot for research, not investment advice.
TORNTPHARM fundamentals at a glance, PE, PB, ROE, ROCE, market cap, dividend yield
How TORNTPHARM ranks against the 2,373 companies in our screener
- TORNTPHARM's market cap of 1.87L Cr ranks in the top 2% of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- TORNTPHARM's book value of ₹248 ranks in the 77th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- TORNTPHARM's promoter holding of 60.8% ranks in the 53rd percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- TORNTPHARM's 3-year profit (PAT) growth of 22.0% ranks in the 59th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- TORNTPHARM's 3-year revenue growth of 13.0% ranks in the 58th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- TORNTPHARM's debt-to-equity ratio of 1.79x is lower than 6% of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
Is TORNTPHARM overvalued? TORNTPHARM P/E vs its Pharma
TORNTPHARM's P/E of 83.9× sits above the Pharma peer median of 33.0×, so on earnings it screens richer than peers, while its 0.77% dividend yield is above the peer median of 0.76%.
TORNTPHARM share price target 2027, 2028, 2029, 2030, 2031, a probability view
Unlike a single guessed number, this is a probability-weighted range from a 10,000-path Monte-Carlo simulation on 9.8y of TORNTPHARM history (19%/yr drift, 22%/yr volatility).
| Year | Low (P10) | Median target (P50) | High (P90) | Upside vs today |
|---|---|---|---|---|
| TORNTPHARM 2027 | ₹4,142 | ₹5,496 | ₹7,292 | +12% |
| TORNTPHARM 2028 | ₹4,106 | ₹6,134 | ₹9,163 | +25% |
| TORNTPHARM 2029 | ₹4,190 | ₹6,846 | ₹11,187 | +39% |
| TORNTPHARM 2030 | ₹4,352 | ₹7,641 | ₹13,416 | +55% |
| TORNTPHARM 2031 | ₹4,584 | ₹8,528 | ₹15,868 | +73% |
Median (P50) is the central estimate; the P10-P90 band is the 80% confidence range. Probabilities, not promises.
What is the probability TORNTPHARM goes up, or doubles?
The bull case for TORNTPHARM
- TORNTPHARM's return on equity of 27.4% ranks in the 92nd percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- A 10,000-path probability model puts a 70% chance the price is higher in a year, with a median target of ₹5,496 (+12%).
- Relatively low volatility (22%/yr), a steadier ride than the typical mid/small-cap.
- Upside scenario: the model's optimistic (P90) 3-year path reaches ₹11,187.
The bear case & risks
- TORNTPHARM's P/E of 83.9x is lower than 13% of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- A steep 19.9× price-to-book means most of the value is intangible/expectations, not assets on the books.
- Downside scenario: the model's pessimistic (P10) 3-year path falls to ₹4,190.
TORNTPHARM volatility & expected range, how bumpy is the ride?
Over the last 9.8 years TORNTPHARM compounded at 19%/year with annualized volatility of 22%. That volatility implies a 1-year 80% range of ₹4,142-₹7,292, the honest backbone behind any single price target.
TORNTPHARM price forecast, the full 60-month probability fan
TORNTPHARM price probability fan
Each band shows where 10,000 simulated paths land. The wider the fan, the more uncertainty.
Probability of key outcomes
What are the odds TORNTPHARM hits common targets within the simulated horizon?
Full multi-horizon detail on the TORNTPHARM price target & forecast page.
TORNTPHARM Piotroski F-Score: 5/8, how financially strong is it?
The Piotroski F-Score grades financial strength on profitability, leverage and efficiency checks. Downstox scores the eight checks it can verify from published filings, so 8 is full marks. TORNTPHARM scores 5/8, mixed financial health.
TORNTPHARM MTF margin & leverage across 11 brokers
Margin Trading Facility lets you buy TORNTPHARM with part of the capital. Lower margin % = higher leverage. Rates compared across 11 brokers (no competitor publishes this):
| Broker | Margin required | Approx. leverage |
|---|---|---|
| Upstox | 23.03% | 4.3× |
| Zerodha | 22.60% | 4.4× |
| Groww | 22.63% | 4.4× |
| Dhan | 22.00% | 4.5× |
| Kotak NeoCHEAPEST | 20.00% | 5.0× |
| Paytm MoneyCHEAPEST | 20.00% | 5.0× |
| Pocketful | 26.50% | 3.8× |
| Fyers | 27.03% | 3.7× |
| Anand Rathi | 26.51% | 3.8× |
| Bajaj Broking | 23.00% | 4.3× |
| Share India | 26.59% | 3.8× |
Compare every broker on the TORNTPHARM MTF page.
TORNTPHARM vs peers,Pharma comparison
| Stock | P/E | Div yield | Market cap |
|---|---|---|---|
| TORNTPHARM (this stock) | 83.9× | 0.77% | ₹1.87L Cr |
| SUNPHARMA | 36.9× | 0.82% | ₹4.67L Cr |
| DIVISLAB | 73.7× | 0.36% | ₹2.20L Cr |
| DRREDDY | 30.4× | 0.68% | ₹97,824 Cr |
| CIPLA | 33.0× | 0.89% | ₹1.18L Cr |
| LUPIN | 18.2× | 0.76% | ₹1.08L Cr |
| AUROPHARMA | 25.5× | 0.24% | ₹96,297 Cr |
Fundamentals from Screener.in, as of 9 Aug 2026
About Torrent Pharmaceuticals Limited: sector, index & market-cap context
Torrent Pharmaceuticals Limited (TORNTPHARM) is a large-cap NSE-listed company in the Pharma sector, and a constituent of the Nifty 500 index, with a market capitalisation of ₹1.87L Cr. See more stocks on our screener.
How the TORNTPHARM Snapshot Score & forecast are built
The Downstox Snapshot Score is a transparent, rules-based read of Torrent Pharmaceuticals Limited's public fundamentals plus a statistical forecast, not an analyst opinion. It rewards low-to-fair valuation, high ROE/ROCE, a strong Piotroski F-Score, a dividend, low volatility and a favourable probability of upside; it penalises rich valuations, weak capital efficiency, a low F-Score and high volatility. The price target is a 10,000-path Monte-Carlo simulation on real historical volatility, a distribution, not a single guess. The bull and bear cases are generated from the same data, so you always see both sides.
This is information, not investment advice. Do your own due diligence and consult a SEBI-registered adviser before investing.
TORNTPHARM analysis, FAQs
Is Torrent Pharmaceuticals Limited (TORNTPHARM) a good buy?
On the numbers, Torrent Pharmaceuticals Limited (TORNTPHARM) worth a closer look, a Downstox Snapshot Score of 59/100, weighing expensive at 83.9× earnings, ROE of 27.4%, a 70% model probability of trading higher in a year. This is a data snapshot for research, not investment advice.
Is TORNTPHARM overvalued or undervalued?
TORNTPHARM trades at 83.9× earnings versus a peer median of 33.0×, so it screens richer than its Pharma peers.
What is the TORNTPHARM share price target for 2031?
TORNTPHARM's probability-weighted 2031 median target is ₹8,528, with an 80% range of ₹4,584-₹15,868 (10,000-path Monte-Carlo).
What is the probability TORNTPHARM doubles in 5 years?
The modelled probability of TORNTPHARM reaching ₹9,848 (2×) within 5 years is 39%.
What is the bull case for TORNTPHARM?
TORNTPHARM's return on equity of 27.4% ranks in the 92nd percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026. A 10,000-path probability model puts a 70% chance the price is higher in a year, with a median target of ₹5,496 (+12%). Relatively low volatility (22%/yr), a steadier ride than the typical mid/small-cap.
What are the risks in TORNTPHARM?
TORNTPHARM's P/E of 83.9x is lower than 13% of the 2,373 NSE companies in our screener, as of 9 Aug 2026. A steep 19.9× price-to-book means most of the value is intangible/expectations, not assets on the books.